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IN VITRO UPTAKE OF DIFFERENT N-TERMINAL VARIANTS OF THE  
BETA-AMYLOID PEPTIDE BY MURINE MICROGLIA 
AMANDA O’DONNELL 
ABSTRACT 
 Alzheimer’s disease is a neurodegenerative disease characterized 
by plaques of amyloid-beta protein (Aβ) and neurofibrillary tangles of the 
microtubule-associated protein tau. Plaques contain several variants of Aβ, 
including full-length Aβ1-40 and Aβ1-42, and N-terminally truncated and cyclized 
pyroglutamate-3 (pE3) Aβ. In particular, pE3 Aβ has been shown to be extremely 
toxic and resistant to degradation. Microglia are phagocytic cells in the brain that 
have been shown to take up and degrade Aβ. The purpose of this study is to 
compare the uptake and degradation of three different Aβ variants: Aβ1-40, Aβ3-40, 
and AβpE3-40 using both primary murine microglia and N9 microglia, a murine 
microglial cell line. The three techniques used to discern the differences in uptake 
and degradation are fluorescence-activated cell sorting, immunofluorescence, 
and Western blot. According to these techniques, primary microglia and N9 
microglia take up and degrade the three Aβ variants differently. Overall, N9 cells 
appear to prefer to take up and degradeAβ1-40, whereas primary microglia prefer 
to take up AβpE3-40 and degrade Aβ1-40.  
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INTRODUCTION 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder for 
which there is no current effective treatment or cure (“Alzheimer’s Disease & 
Dementia | Alzheimer’s Association,” 2013). It is the overall sixth leading cause 
of death in the United States, and is the fifth leading cause of death of persons 65 
and older (“Latest Facts & Figures Report | Alzheimer’s Association,”2014). 
Current studies estimate that there are 5.2 million people across America that 
suffer from AD, with that number projected to rise to nearly 7.1 million by 2025 
and a shocking 13.8 million by 2050 (“Latest Facts & Figures Report | 
Alzheimer’s Association,” 2014).  Even more strikingly, there is a 68% reported 
increase in the number of AD-related deaths between 2000 and 2010 (“Latest 
Facts & Figures Report | Alzheimer’s Association,” 2014). With the number of 
patients diagnosed with AD disease on the rise, healthcare costs associated with 
the disease also continue to increase. It is estimated that the cost of caring for 
people with AD will rise to a staggering $1.2 trillion by the year 2050 (“Latest 
Facts & Figures Report | Alzheimer’s Association,” 2014). This includes the cost 
of health care, long-term care, and hospice (“Latest Facts & Figures Report | 
Alzheimer’s Association,” 2014). The impact of AD on the United States, as well 
as the rest of the world, cannot be ignored and will only get worse as the 
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population continues to age. There are currently an estimated 44.4 million people 
living with dementia worldwide (“Reports | Alzheimer’s Association,” 2014). 
The need for an effective way to prevent and treat AD continues to rise as more 
and more people around the world develop this debilitating disease.  
AD is not just a disease of old age. Early onset AD (onset before age 65) 
affects as many as 200,000 people in the United States (“Younger/Early Onset | 
Alzheimer’s Association,” 2014). As many as 95% of cases of AD have a late 
onset and are sporadic, with about 5% of cases being familial with an earlier 
onset (Hunter, Arendt, & Brayne, 2013). It is the most common cause of dementia 
in the elderly, and usually manifests with impaired cognitive function, 
disorientation, memory loss, altered mood, and behavior (Kumar, Abbas, & 
Aster, 2012). These neurodegenerative symptoms may be caused by the build-up 
of plaques of amyloid-beta protein and a slowed clearance of these peptides in 
the brain (Kumar et al., 2012). Current treatments include the drug Aricept, a 
cholinesterase inhibitor. Aricept works by preventing the breakdown of 
acetylcholine in the brain, making this neurotransmitter more readily available. 
This drug is aimed at slowing the cognitive effects of AD (memory loss, 
confusion, problems with reasoning), but it does nothing to treat the underlying 
pathology (“Latest Treatment Options | Alzheimer’s Association,” 2014). 
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Current AD research is aimed at treating the underlying pathology of the disease 
as opposed to just the symptoms of the disease. 
AD is characterized by pathological plaques of beta amyloid protein and 
neurofibrillary tangles of the microtubule-associated protein tau. Cleavage of the 
amyloid precursor protein (APP) by α-secretase and γ-secretase results in the 
release of a non-pathogenic protein. Amyloid-beta protein is formed when APP 
is cleaved by “β-site APP-cleaving enzyme-1 (BACE 1), followed by γ-secretase” 
(Alhibshi, Gotoh, & Suzuki, 2013).  These plaques of amyloid-beta protein also 
lead to an increased level of phosphorylation of the tau protein which can bind to 
neuronal microtubules, forming tangles which can lead to more neuronal 
dysfunction (Kumar et al., 2012). Hyperphosphorylated tau is also found in 
dystrophic neurites associated with fibrillar amyloid plaques (Krstic & Knuesel, 
2013). Mutations in Presenilins (components of the γ-secretase enzyme complex) 
or APP can increase the rate that Aβ is generated or shift the ratio of A42:40 and 
can lead to early-onset, familial forms of AD (Kumar et al., 2012). In a paper 
published by Hunter, et. al. in early 2013, it was stated that “no disease pathway 
has been fully accepted, and there are no treatments that prevent, stop or reverse 
the cognitive decline associated with AD” (Hunter et al., 2013). According to the 
Alzheimer’s Association, it is the only disease among the top ten causes of death 
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in United States that has no cure, no way to prevent it, or even no way to stop its 
progression (“Latest Facts & Figures Report | Alzheimer’s Association,” 2014). 
It is known that there are several variants of the Aβ peptide. Two of the 
most well known C-terminal variants of Aβ include Aβ1-40 and Aβ1-42. One of the 
Aβ peptide variants that has been receiving a lot of attention in recent years is the 
amino-terminally truncated pyroglutamate-3 (pE3) Aβ (Nussbaum et al., 2012). 
This modification is catalyzed by the enzyme glutaminyl cyclase (QC) (Hartlage-
Rübsamen et al., 2011). QC causes the cyclization of the glutamic acid of the N-
terminally truncated Aβ protein, which leads to a loss of N-terminal charge 
(Hartlage-Rübsamen et al., 2011). Interestingly enough, the QC protein and 
mRNA is upregulated in the brains of patients with AD (Schilling et al., 2008). 
An increase in the concentration of AβpE3-42 was found in the brains of patients 
with AD when compared to the brains of individuals without the disease, further 
linking QC to pE3-Aβ production (Schilling et al., 2008). This loss of charge 
results in an accelerated aggregation of pE3-Aβ and subsequently can cause co-
aggregation of non-pE3 Aβ peptides (Hartlage-Rübsamen et al., 2011). This is 
further supported by the evidence that administration of a QC inhibitor leads to 
improved memory, improved learning, and reduced levels of both pE3-Aβ and 
conventional Aβ (Nussbaum et al., 2012). Due to the loss of charge at the N-
terminus, the solubility of pE3-Aβ is decreased at physiological pH, which adds 
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to the increased aggregation of this peptide (Schlenzig et al., 2012). The pE-Aβ3-40 
variant is also frequently arranged in bundles when compared to Aβ1-40 
(Schlenzig et al., 2012). It has been suggested that a reduction of pE3-Aβ could 
prevent Aβ aggregation and could ultimately enhance neuronal survival since 
pE3-Aβ is a known seeding peptide (Schilling et al., 2008). A recent study 
conducted by our lab showed that pE3-Aβ is a major species found in both 
diffuse and focal Aβ deposits and vascular amyloid deposits in human, vervet, 
canine, and transgenic mouse brain (Frost et al., 2013). In addition to pE3-Aβ, 
pE11-Aβ has also shown to form the central core of Aβ plaques, indicating that its 
properties are similar to that of pE3-Aβ (Perez-Garmendia & Gevorkian, 2013). 
The pE11-Aβ peptide is also suggested to be a seeding peptide, as it has been 
demonstrated to accumulate in the brain before the onset of clinical symptoms in 
the early stages of AD (Perez-Garmendia & Gevorkian, 2013).    
Recent preclinical immunotherapy studies have been aimed at targeting 
pE3-Aβ. One study showed that passive immunization with a highly specific 
anti-pE3-Aβ antibody showed reduced Aβ, pE3-Aβ, and fibrillar amyloid 
deposits in the hippocampus and cerebellum (Frost et al., 2012). There results 
were observed after both a preventative study in mice showing the early stages 
of plaque deposition and a therapeutic study in mice showing advanced Aβ 
plaque deposition and gliosis (Frost et al., 2012). In addition, this study showed 
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that the amount of general Aβ and fibrillar deposits were reduced beyond what 
would be expected from the clearance of pE3-Aβ, indicating that new plaque 
formation may be prevented by the removal of pE3-Aβ (Frost et al., 2012). 
Selective targeting of pE3-Aβ may therefore be useful in treating or preventing 
AD in patients who are in the early stages of the disease (Frost et al., 2012). 
Microglial cells are immune cells of the central nervous system which 
share an ancestry with macrophages and represent 20% of total glial population 
and 10% of all brain cells (Vilhardt, 2005). Similar to macrophages, microglia 
function to phagocytose dead tissue, microbes, and foreign matter (Kumar et al., 
2012). Interestingly, microglia have been shown to have a biphasic 
neuroprotective-neurodegenerative role in AD (Mizuno, 2012). Fibrillar and 
oligomeric Aβ have been shown to activate microglia, and as a result, the 
microglia release proinflammatory cytokines such as interleukin-1, interleukin-6, 
and tumor-necrosis-factor-α (Mizuno, 2012). Activated microglia also release 
chemokines, complement components, free radicals, and glutamate, which 
enhance the neurotoxicity of microglia via inflammation (Mizuno, 2012). The 
neuroprotective role of microglia lies in the cells’ ability to phagocytose and 
degrade Aβ, in addition to releasing anti-inflammatory cytokines and anti-
oxidants  (Mizuno, 2012). Tapping into the neuroprotective role of microglia 
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while avoiding the factors that contribute to their neurotoxicity may prove to be 
an effective treatment for AD.  
It has also been suggested that severe systemic inflammation may 
contribute to the role microglia play in neurodegenerative diseases 
(Cunningham, 2013). The concept of microglial “priming” is discussed, in which 
during chronic neurodegenerative disease the brain shows an exaggerated 
response to a systemic inflammatory response (Cunningham, 2013). This follows 
from the idea that under normal circumstances, microglia clear the brain of 
harmful debris while causing minimal damage to the surrounding tissue, but 
with chronic neurodegeneration, microglia may be present at a higher than 
normal activation state and may release factors that promote inflammation and 
cause damage to the surrounding tissue (Cunningham, 2013).  Clinical evidence 
for these claims has also been shown. In a general practitioner database review, 
two or more infections of any type over a four year period doubled the risk of 
AD in patients, and further studies significantly associated overall poor health 
with cognitive decline (Dunn, Mullee, Perry, & Holmes, 2005).  
A previous study from our lab has shown that primary microglia from B6 
mice have successfully taken up and degraded fluorescently labeled fibrillar Aβ42 
(Fu et al., 2012). These murine microglia have been shown to take up fibrillar 
Aβ42 both in vitro, using fibrillar Aβ42 synthesized in the lab, and in vivo, using 
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amyloid cores extracted from the brains of AD patients (Fu et al., 2012). The same 
study showed that the phagocytosed fibrillar Aβ42 was degraded, shown by a 
decrease in the amount of fibrillar Aβ42 in the cell lysate after a six-hour washout 
period (Fu et al., 2012). It was also shown that internalized fibrillar Aβ42 
colocalized with lysosomal markers (lysotracker red and LAMP-1) in vitro, 
further suggesting that internalized fibrillar Aβ42 is transported to the lysosomes 
(Fu et al., 2012). My study aims to use a similar method as described in Fu et al. 
to investigate the uptake of monomeric and fibrillar Aβ1-40, Aβ3-40, and AβpE3-40 
using N9 microglia and primary microglia from C57BL/6 (B6) mouse pups. The 
internalization and possible degradation of these different Aβ variants will be 
compared using Western blot, fluorescence activated flow cytometry (FACS), 
and confocal microscopy.  
As previously stated, my study aims to address the issue of clearance of 
different variants of the Aβx-40 peptide. No other known study has attempted to 
determine the differences in how microglia phagocytose and degrade monomeric 
and fibrillar Aβ1-40, Aβ3-40, and AβpE3-40. By discerning the differences in uptake 
and degradation between these variants, we can develop treatments that 
stimulate microglia to phagocytose and degrade Aβ peptides and to lower other 
effector functions that may contribute to AD pathology. 
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SPECIFIC AIMS 
In order to determine if different variants of the Aβ peptide are taken up 
and degraded differently by primary and immortalized murine microglia, I will: 
 Use confocal microscopy to determine if applied Aβx-40 is indeed 
internalized 
 Use fluorescence-activated cell sorting to determine if the uptake of 
Aβx-40 by microglia is concentration dependent 
 Determine by Western blot the differences in supposed 
internalization and degradation of monomeric and fibrillar Aβ1-40, 
Aβ3-40, and AβpE3-40 following a number of washout periods 
 Perform statistical analysis concerning uptake and degradation 
between monomeric and fibrillar Aβ1-40, Aβ3-40, and AβpE3-40 using 
N9 microglia. 
These studies should demonstrate the differences, if any, between the uptake and 
degradation of monomeric and fibrillar Aβ1-40, Aβ3-40, and AβpE3-40 using N9 and 
primary murine microglia. We hope these studies will give us a better insight 
into the microglial uptake and clearance of the different variants of beta amyloid. 
In addition, this study will help us determine if Aβ is processed differently by N9 
and primary microlia. This information can be used to develop further studies 
using immunotherapy to target these proteins for degradation.   In particular, the 
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results of these studies will help to determine if there are differences in the 
effects of specific antibodies (target and Ig isotype) on microglial clearance of A 
protein. 
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MATERIALS AND METHODS 
 
Primary Microglia Preparation 
Primary microglia were isolated from 1-3 day old B6 mouse pups by a 
modification of methods previously described (Giulian and Barker. 1986; Fu et al 
2012). Animals were sacrificed through cervical dislocation and decapitation in 
accordance with protocols approved by the Harvard Medical Area Standing 
Committee on Animals and in accordance with all state and federal regulations. 
The brain was removed above the cerebellum and placed in a petri dish 
containing ice-cold Hanks balanced salt solution (HBSS) (Life Technologies, 
Woburn, MA) under a dissection microscope. The meninges, blood vessels, and 
olfactory bulb were removed and the cortices were collected in ice-cold HBSS. 
Following collection of all the mouse pup brains, they were transferred to 10ml 
of a trypsin (Life Technologies, Woburn, MA) solution (0.25% trypsin in serum-
free DMEM; Life Technologies, Woburn, MA) and incubated at 37o C for 15 
minutes with gentle shaking. Following the incubation, 10 ml DNAse (Roche, 
Minneapolis, MN) solution [200 μg/ml final concentration in DMEM/ 10% FBS 
(Life Technologies, Woburn, MA)/ Pen-Strep (Life Technologies, Woburn, MA)/ 
Fungizone (Life Technologies, Woburn, MA)] was added to stop the 
trypsinization and incubated at room temperature for 5 minutes. The tissue was 
further broken up by pipetting the entire solution up and down five times 
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followed by incubation at room temperature for 5 minutes. The homogenate was 
filtered into a 50 ml Falcon tube using a 100 μm cell strainer, followed by 
centrifugation for 10 minutes at 1100 rpm. The supernatant was aspirated and 
the pellet was resuspended in warm DMEM/ 10% FBS/ Pen-Strep/ Fungizone. 
The solution was filtered through a 70 μm cell strainer into a new 50 ml Falcon 
tube. Cell culture flasks were incubated with Poly-L-Ornithine (Sigma, St. Louis, 
MO) for 2 hours before use.  Cells from 2-3 Pups were seeded into 1 Poly-L-
Ornithine coated T75 flask. DMEM/ 10% FBS/ Pen-Strep was added to make a 
final volume of 15 ml in the flask. The flasks were labeled with the mouse 
species, preparation number, number of pups per flask, and the date of 
preparation. The flasks were then incubated at 37o C for 24 hours. On day 1 post-
isolation, the flasks were tapped gently and the cells were washed 1x with 10 ml 
warm sterile Phosphate Buffered Saline (PBS) (Lonza, Hopkinton, MA). Fresh 
medium (15 ml) was then added to the cells. There was no medium change on 
days 2-7 post-isolation. On day 8 post-isolation the medium was changed to fresh 
DMEM/ 10% FBS/ Pen-Strep/ Fungizone + mMCSF (R&D Systems, 
Minneapolis, MN)(10 ng/ml final concentration). The microglia were ready to 
harvest 10 days after the start of mMCSF-stimulation (day 18 post-isolation). The 
medium was thereafter changed twice per week.  
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Obtaining Microglia 
The flasks were tapped gently while being held level to the lab bench. The 
supernatant was taken up and put into a 50 ml Falcon tube. Fresh medium (10 
ml, no mMCSF) was added to the flasks and the flasks were tapped while being 
held level to the lab bench again. The medium was taken out and added to the 50 
ml Falcon tube containing the supernatant. The supernatant was centrifuged at 
1100 rpm for 10 minutes. The supernatant, which contained the medium, was 
aspirated and the pellet was resuspended in 1000 μl DMEM/ 10% FBS/ Pen-
Strep/ Fungizone + 10 ng/ml mMCSF using a P1000 pipette. Trypan blue 
(Sigma, St. Louis, MO) (10 μl) was added to 10 μl of the cell suspension. The cells 
were then counted using a light microscope to determine the number of cells 
present per ml. The cells were then seeded at the density needed for certain 
experiments in DMEM/ 10% FBS/ Pen-Strep/ Fungizone + 10 ng/ml mMCSF. 
The cells were then incubated at 37o C for 30 minutes and washed 2x with warm 
sterile PBS to remove debris. Fresh DMEM/ 10% FBS/ Pen-Strep/ Fungizone + 
10 ng/ml mMCSF was then added to the wells and the cells were incubated at 
37o C until needed for an experimental procedure. 
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N9 Microglia Cell Culture 
The N9 microglial cell line was initially generated by Professor Paola 
Castagnoli, who is currently the Scientific Director at the Singapore Immunology 
Network (SigN)Biopolis, and provided to us with her permission from Dr. 
Joseph El Khoury (Massachusetts General Hospital, Boston, MA). N9 cells are a 
murine microglial cell line immortalized by the inclusion of the v-raf and v-myc 
oncogenes (Blasi et al., 1985). N9 microglia cells were cultured in a 75-cm2 cell 
culture flask (Sigma, St. Louis, MO) in 15 ml RPMI-1640 (Life Technologies, 
Woburn, MA)/ 10% FBS/ Pen-Strep/ Fungizone. For experimental procedures 
and passaging, N9 microglia were harvested from the culture flasks 
enzymatically by incubation for 5 minutes at 37 C with 3 ml of trypsin (1x). The 
flask was tapped gently until all of the cells detached from the plastic. 
Neutralization of the trypsin was performed by adding 3 ml of RPMI-1640 
medium / 10% FBS/ Pen-Strep/ Fungizone to the flask and the cells were then 
pelleted by centrifugation at 1100 rpm for 5 minutes at room temperature and 
resuspended in 5 ml of RPMI-1640/ 10% FBS/ Pen-Strep/ Fungizone. The cells 
were plated at a 1:50 dilution bi-weekly in 15 ml RPMI-1640/ 10% FBS/ Pen-
Strep/ Fungizone. Trypan blue (10 μl) was added to 10 μl of the cell suspension 
and cells were quantified using a haemocytometer and a light microscope to 
determine the number of cells present per ml. The cells were then seeded at the 
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density needed for certain experiments in RPMI-1640/ 10% FBS/ Pen-Strep/ 
Fungizone. 
 
Double Immunofluoresence (IF) 
Primary and N9 microglia were plated in three glass-bottom dishes each 
at a density of about 1 X 105 cells per dish. One dish served as a negative control 
and contained only serum-free RPMI (N9) or DMEM (primary microglia) 
medium. This experiment used fluorescently labeled fibrillar Aβ1-40, Aβ3-40, and 
AβpE3-40, heretofore referred to as FLfAβ1-40, FLfAβ3-40, and FLfAβpE3-40. The Aβ1-40, 
Aβ3-40, and AβpE3-40 peptides were a kind gift from our collaborators at 
Probiodrug AG, Halle, Germany. The peptides were then labeled in the lab by 
Dr. Holger Cynis and Dr. Helen Crehan using an Alexa Fluor 488 Protein 
Labeling Kit (Life Technologies, Woburn, MA). Three dishes were used per 
peptide. One dish served as a negative control, one dish contained 0.5 μM of Aβx-
40, and the last dish contained 8 μM of Aβx-40 (see Table 1). After the four dishes 
were incubated at 37° C for one hour, the cell culture supernatant was then taken 
off and the cells were rinsed 1x with 0.1 M Tris buffer (pH 7.6). All dishes were 
fixed with 4% paraformaldehyde (PFA) (Electron Microscopy Sciences, Hatfield, 
PA) in PBS for 10 minutes at room temperature. Cultures were washed three 
times with 0.1 M Tris buffer. The cells were immersed in 0.1 M Tris buffer and 
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were incubated at room temperature for five minutes. Cells were then blocked 
with 2% goat serum in 0.1 M Tris buffer and incubated at room temperature for 
five minutes to combat non-specific binding of the secondary antibody. The 
primary antibodies were diluted in 2% goat serum in 0.1 M Tris. The cells were 
counterstained with an anti-CD11b antibody (rat anti-mouse, 1:500) (AbD 
Serotec, Raleigh, NC). The cells were covered in 500 μl of the antibody solution 
and were incubated at 4o C in a humidified chamber overnight. The next day, the 
cells were warmed up to room temperature. The primary antibodies were rinsed 
off with 0.1 M Tris and the cells were immersed in 2% goat serum (Life 
Technologies, Woburn, MA) in 0.1 M Tris for 5 minutes. The secondary antibody 
used was an AlexaFluor 594 goat anti-rat (Life Technologies, Woburn, MA). The 
secondary antibody was diluted in 2% goat serum in 0.1 M Tris (1:500). The 
diluted fluorescently labeled secondary antibody was mixed using the vortex for 
a few seconds to ensure even distribution of the antibody in the buffer. The 
diluted fluorescently labeled secondary antibody mixture was added to each 
dish at a volume of 500 μl per dish. The cells were then incubated at room 
temperature for two hours in a humidified chamber. The secondary antibodies 
were then rinsed off with 0.1 M Tris followed by immersion of the cells in 0.1 M 
Tris twice for 20 minutes each. Cultures were mounted with a coverslip using 
VectaShield mounting medium with DAPI (Vector Laboratories, Burlingame, 
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CA) and stored in the dark at 4 C until viewing on a Zeiss LSM 710 Confocal 
Microscope.  
Experiments were also conducted to discern the purity of the microglial 
cultures. Primary microglia were plated in four glass-bottom dishes at a density 
of 1 X 105 cells per dish. The protocol followed for double immunofluorescence 
was the same as previously stated using the following antibodies: Iba1 (rabbit 
1:500) (Wako Chemicals, Richmond, VA and CD11b (rat 1:500). Both of these 
antibodies recognize microglia. The secondary antibodies used in this 
experiment were AlexaFluor 488 (goat anti-rabbit, 1:500), and AlexaFluor 594 
(goat anti-rat 1:500). A characterization experiment was also conducted for the 
N9 cells. The primary antibodies used were CD11b, a macrophage antigen (rat 
1:500) (AbD Serotec, Raleigh, NC), Iba-1, found on activated macrophages and 
microglia (rabbit 1:500), and CD45, a leukocyte antigen (rat 1:500) (AbD Serotec, 
Raleigh, NC), and the secondary antibodies used were AlexaFluor 488 (goat anti-
rabbit 1:500) (Life Technologies, Woburn, MA). See Table 2 for full antibody 
listing. The confocal images were obtained using a Zeiss LSM 710 Confocal 
Microscope. The software used to obtain the images was ZEN Black (Carl Zeiss 
Microscopy, Peabody, MA). Images were obtained by setting the laser to 
wavelengths appropriate to the secondary antibody used.  The images were 
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analyzed using ZEN Blue software (Carl Zeiss Microscopy, Peabody, MA). The 
final images were arranged in Microsoft Power Point. 
Dish 
Number 
Condition Primary 
Antibody 
Secondary Antibody 
1 No Abeta Control CD11b AlexaFluor 594 
2 0.5 μM Aβ CD11b AlexaFluor 594 
3 8 μM Aβ CD11b AlexaFluor 594 
 
 
 
 
 
 
Cell Type Primary 
Antibodies 
Secondary Antibodies 
PMG Iba-1, CD11b AlexaFluor 488, 
AlexaFluor 594 
N9 Iba-1 AlexaFluor 488 
N9 CD11b AlexaFluor 594 
N9 CD 45 AlexaFluor 594 
N9 CD 68 AlexaFluor 594 
 
 
 
Aβ Uptake and Degradation Assay 
Aβ uptake assays were conducted using monomeric and fibrillar Aβ1-40, 
Aβ3-40, and AβpE3-40 as described in Table 3. These peptides were not fluorescently 
labeled. Microglia cells were plated in 5 wells of a 12-well plate at a density of 4 
X 105 (N9) or 2-4 X 105 (primary microglia) per well. The first well served as a 
negative control and contained only serum-free RMPI (N9) or DMEM (primary 
Table 1. FLfAβ Uptake Experimental Conditions 
This experiment was performed using both 
primary and N9 microglia. 
Table 2. Antibodies Used for Characterization Experiments 
Characterization experiments were performed for primary and N9 
microglia using several antibodies. 
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microglia), which was collected after 1 hour incubation period. The remaining 
four wells contained Aβx-40 at a concentration of 8 μM. The second well was 
incubated with Aβx-40 for 1 hour. In the third, fourth, and fifth wells, the medium 
containing Aβx-40 was discarded after 1 hour and the cells were washed 2x with 
warm PBS. Fresh medium was then applied and remained on the cells for 1 hour, 
3 hours, and 6 hours, respectively (see Table 3 for complete listing of experiment 
conditions). After the medium was collected from each respective sample, the 
cells were washed 2x with warm PBS and T-PER Tissue Protein Extraction 
Reagent (Thermo Scientific, Pittsburgh, PA) was applied to the cells for 2 
minutes. The buffer was pipetted up and down and the extract was collected. 
After the samples were collected, they were placed on ice and then frozen. 
Well Number Contains 
Cells 
Contains 
Aβ 
Incubation 
Period with 
Aβ 
Washout Period 
1 Yes No None 
None, Medium and lysate was 
collected at the same time as Well 2 
2 Yes Yes 1 hour 
None, Medium and lysate was 
collected after 1 hour incubation 
period with Aβ 
3 Yes Yes 1 hour 1 hour 
4 Yes Yes 1 hour 3 hours 
5 Yes Yes 1 hour 6 hours 
 
 
 
 
Table 3. Aβ Uptake and Degradation Assay Experimental 
Conditions 
The above table lists the experimental conditions for the Aβ uptake 
experiments using N9 and primary microglia. For wells 3, 4, and 5 
medium and lysate was collected after each respective washout period. 
The experiment was performed once for primary microglia and 3 times 
for N9 cells. 
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Protein Concentration Determination 
A Pierce BCA Protein Assay Kit (Thermo Scientific. Pittsburgh, PA) was 
used to determine the protein concentration of the unknown samples. The 
samples were diluted 1:4 in PBS and plated in a 96-well plate. Pierce BCA Protein 
Reagent A was added to Pierce BCA Protein Reagent B, which was then added to 
the wells at a volume of 190 μl. The plate was incubated at 37o C for 25 minutes.  
After incubation, the absorbance of each well containing standards or samples 
was measured in a Bio-Rad ELISA plate reader at 562 nm. A standard curve was 
generated using a bovine serum albumin stock solution (2 mg/ml) diluted in PBS 
at the following concentrations: 2 mg/ml, 1.5 mg/ml, 1 mg/ml, 0.75 mg/ml, 0.5 
mg/ml, 0.25 mg/ml, 0.125 mg/ml, and a PBS blank.  
 
Western Blot Analysis 
The samples obtained from the Aβ uptake and degradation assay were 
analyzed by Western blot.  Western blotting is a method used to separate and 
identify proteins of interest. It only identifies the proteins present. Denaturing 
gels were used so that single proteins could be identified by immunoblotting 
with antibodies directed against epitopes of the protein of interest. The samples 
were separated by gel electrophoresis using a NuPAGE 12% Bis-Tris Mini Gel 
(Life Technologies, Woburn, MA) and were prepared for gel electrophoresis by 
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adding 5 μl of NuPAGE LDS Sample Buffer (4x) (Life Technologies, Woburn, 
MA) and 5 μl of NuPAGE Reducing Agent (10x) (Life Technologies, Woburn, 
MA) to 13 μl of sample (primary microglia) or 12 μg (N9 microglia). They were 
then heated to 70° C for ten minutes to denature the proteins. SDS running buffer 
was prepared by adding 50 ml of 20x NuPAGE MES SDS Running Buffer (Life 
Technologies, Woburn, MA) to 950 ml deionized water. The upper and lower 
buffer chambers were filled with 1x running buffer. Since reduced samples were 
used, 500 μl NuPAGE Antioxidant (Life Technologies, Woburn, MA) was added 
to the upper buffer chamber. The pre-stained protein marker (Life Technologies, 
Woburn, MA) was loaded on the gel with 10 μl loaded into the first well. The 
sample was then loaded onto the gel at a volume of 20 μl per well. The gel was 
run at constant voltage (200 V) for 35 minutes. The proteins on the gel were then 
transferred to a PVDF membrane. The membrane was activated in methanol (200 
proof) for 30 seconds and was then rinsed in transfer buffer. New transfer buffer 
was prepared by adding 750 ml of deionized water to 50 ml of NuPAGE Transfer 
Buffer (20x) (Life Technologies, Woburn, MA) and 200 ml of methanol (200 
proof). Two pieces of wadding and 3MM paper also cut to the size of the gel 
were pre-soaked in cold transfer buffer. After equilibration, the gel was 
transferred to a cassette. The order of placement within the cassette was cotton, 
3MM filter paper, gel, PVDF membrane, 3MM filter paper and cotton. The 
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cassette was slotted into its holder and placed into the tank filled with transfer 
buffer, in the cold room (4 C). The transfer was run at constant current (300 mA) 
for 2 hours. Following transfer, the membrane was removed from the gel transfer 
apparatus and blocked in a staining dish using 10 ml of Odyssey blocking buffer 
(Li-Cor, Lincoln, NE) diluted 1:1 with PBS for 1 hour. Primary antibody (6E10, 
mouse monoclonal) (Covance, Dedham, MA) was diluted 1:1000 in the Odyssey 
blocking buffer and was incubated with the membrane at 4 C in a humidified 
chamber overnight. The membrane was washed 4 times for 5 minutes each at 
room temperature in PBS + 0.1% Tween-20 with gentle shaking. The 
fluorescently-labeled secondary antibody (AlexaFluor IR-Dye 800 goat anti-
mouse) (Li-Cor, Lincoln, NE) was diluted 1:10,000 in Odyssey blocking buffer. 
The membrane was incubated with the secondary antibody for 1 hour with 
gently shaking while being protected from light. The membrane was then 
washed 4 times for 5 minutes each at room temperature in PBS + 0.1% Tween-20 
(Sigma, St. Louis, MO)  + 0.1% SDS (Sigma, St. Louis, MO) with gentle shaking 
while being protected from light. The membrane was rinsed with PBS to remove 
residual Tween-20. The membrane was scanned using an Odyssey Infrared 
Imaging System. After analysis, the membrane was dried, wrapped in plastic 
and stored at 4° C. Western blots for the uptake and degradation experiments 
using N9 cells were performed 3 times and those presented here are 
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representative. Similar experiments were only performed once using primary 
microglia. Blots were routinely re-probed for GAPDH (rabbit polyclonal, 1:2000) 
(Abcam, Cambridge, MA) as a loading control to ensure equal loading of protein, 
which was also used for densitometry. 
 
Fluorescence-Activated Cell Sorting (FACS) Analysis 
N9 and primary microglia cells were plated in a 12-well plate at a density 
of 4 X 105 cells per well. The first well was a negative control and contained only 
serum-free RMPI medium. The second well contained a PE-Cy5 Rat IgG2b 
isotype control antibody (1:250 dilution) (BD Biosciences, San Jose, CA). The 
third well contained CD11b (Rat monoclonal antibody, 1:250 dilution) (Abcam, 
Cambridge, MA). The fourth well contained fluorescently labeled fibrillar (FLf) 
Aβ1-40 (0.5 μM) and CD11b (Rat monoclonal antibody, 1:250 dilution). The fourth 
well contained FLfAβ1-40 (2 μM) and CD11b (Rat monoclonal antibody, 1:250 
dilution). The sixth well contained FLfAβ1-40 (8 μM) and CD11b (Rat monoclonal 
antibody, 1:250 dilution). See Table 4 for a list of experimental conditions. The 
cells were washed 1x with warm PBS. The above solutions were placed on the 
cells, and the cells were incubated for one hour at 37° C. After incubation, the 
supernatant was taken up and the cells were rinsed 1x with warm PBS. In each 
well, 500 μl of Accutase (Millipore, Billerica, MA) was added to detach the cells 
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from the plastic, and the cells were placed back in the incubator for 10-15 
minutes, until all cells were detached. The cells were then transferred into 
labeled polystyrene round bottom FACS tubes and were ready for analysis. This 
experiment was repeated using FLfAβ3-40 and FLfAβpE3-40.  
 
Well Number Condition 
1 Cells + IgG2b Isotype Control 
2 Cells + CD11b 
3 Cells + 0.5 μl FLfAβx-40 + CD11b 
4 Cells + 2 μl FLfAβx-40 + CD11b 
5 Cells + 8 μl FLfAβx-40 + CD11b 
 
 
 
 
Statistical Analysis 
GAPDH was used as the loading control. Western blot bands were 
analyzed using Li-Cor Odyssey software, and values were reported as an 
integrated intensity ratio normalized to GAPDH. Statistics were performed using 
GraphPad Prism software. The cell lysate integrated intensity values for the Aβ 
Table 4. FACS Analysis Experimental Conditions 
Both FACS experiments using N9 and primary microglia were 
conducted using the above listed conditions. The experiment using N9 
cells also contained a well with unstained microglia. 
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uptake assay were normalized to the 1 hour incubation time point and were then 
analyzed by one-way repeated measures ANOVA and post-hoc Tukey test.  
 
RESULTS 
Characterization of Primary and N9 Microglia 
 A characterization experiment was done with the N9 microglia to 
determine which markers the cells express. The N9 cells were plated in one glass 
bottom dish and were stained for both Iba-1 and CD11b to see if the two proteins 
colocalized using the antibodies (Figure 1). In addition to this, the N9 cells were 
plated in three different glass-bottom dishes and were stained for Iba-1, CD11b, 
and CD68 (Figure 2). Staining with all three antibodies was observed, indicating 
that this cell line was positive for 3 different microglial markers. 
To ensure that the microglia harvested from the primary culture were 
mainly microglia, cells were plated in glass-bottom dishes and stained for Iba-1 
and CD11b (Figure 3). The Iba-1 staining co-localized with the CD11b staining, 
indicating that the cells obtained were in fact microglia. The figure also shows 
that the DAPI staining colocalized with the Iba-1 and CD11b staining. 
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Figure 1. Characterization of N9 Microglia 
N9 microglia were stained with DAPI (blue, stains DNA), anti-Iba-1 (green, Alexa Fluor488) 
and anti-CD11b (Red, Alexa Fluor 594) antibodies and scanned at 20x (A) and 63x (B) 
magnification on a confocal microscope. Iba-1 and CD11b are both microglial markers and 
were colocalized at both magnifications. This colocalization shows that the cells in the cells 
obtained from the culture were indeed microglia. 
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Figure 2.  Additional Characterization of N9 Microglia 
N9 microglia were stained with anti-Iba-1 (green, Alexa Fluor 488) anti-
CD11b (red, Alexa Fluor 594), and anti-CD 68 (red, Alexa Fluor 594) 
antibodies and were scanned at 20x magnification using a confocal 
microscope.   
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Figure 3. Characterization of Primary Microglia 
Primary microglia were stained with DAPI (blue, stains DNA), anti-Iba-1 (green, Alexa Fluor 
488) and anti-CD11b (Red, Alexa Fluor 594) antibodies and scanned at 20x (A) and 63x (B) 
magnification on a confocal microscope. Iba-1 and CD11b are both microglial markers and are 
colocalized at both magnifications. This colocalization shows that the cells in the cells 
obtained from the culture are indeed microglia.  
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Uptake of Aβx-40 is Concentration Dependent as Shown By FACS 
 
As shown in Figure 4, the uptake of Aβx-40 by N9 microglia was 
concentration dependent. Furthermore, the intracellular levels of each separate 
peptide, Aβ1-40, Aβ3-40, and AβpE3-40 seem to have increased respectively.  At a 
concentration of 0.5 μM, only 0.39% of the cells incubated with Aβ1-40 were in the 
upper right quadrant (i.e. positive for both CD11b and fluorescently labeled A 
peptide indicating uptake of the A peptide by N9 cells), 4.14% of the cells 
incubated with Aβ3-40 were in the upper right quadrant, and 6.97% of the cells 
incubated with AβpE3-40 were in the upper right quadrant. The number of cells 
positive for Aβx-40 increased when 2 μM of protein was applied to the cells. At 
this concentration, 1.37% of the cells incubated with Aβ1-40 were in the upper 
right quadrant, 13.7% of the cells incubated with Aβ3-40 were in the upper right 
quadrant, and 21.8% of the cells incubated with AβpE3-40 were in the upper right 
quadrant. At the highest concentration, 8 μM, the percentage of cells positive for 
Aβx-40 was even further increased. At this concentration, 19.3% of the cells 
incubated with Aβ1-40 were in the upper right quadrant, 32.3% of the cells 
incubated with Aβ3-40 were in the upper right quadrant, and 41.4% of the cells 
incubated with AβpE3-40 were in the upper right quadrant. 
The uptake of Aβ by primary microglia also increased with concentration. 
The percentages associated with each concentration of Aβ were lower than the 
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corresponding values for the N9 microglia. Despite this fact, the uptake of Aβx-40 
by primary microglia, as shown in Figure 5, was also concentration dependent. 
Unlike N9 cells, the intracellular levels of each separate peptide, Aβ1-40, Aβ3-40, 
and AβpE3-40, did not seem to increase when compared to one another.  At a 
concentration of 0.5 μM, only 7.07% of the cells incubated with Aβ1-40 were in the 
upper right quadrant, 7.47% of the cells incubated with Aβ3-40 were in the upper 
right quadrant, and 4.12% of the cells incubated with AβpE3-40 were in the upper 
right quadrant. The number of cells positive for Aβx-40 increased when 2 μM of 
protein was applied to the primary microglia. At this concentration, 50.5% of the 
cells incubated with Aβ1-40 were in the upper right quadrant, 20.7% of the cells 
incubated with Aβ3-40 were in the upper right quadrant, and 10.1% of the cells 
incubated with AβpE3-40 were in the upper right quadrant. At the highest 
concentration, 8 μM, the percentage of cells positive for Aβx-40 was even further 
increased. At this concentration, 51.4% of the cells incubated with Aβ1-40 were in 
the upper right quadrant, 54.8% of the cells incubated with Aβ3-40 were in the 
upper right quadrant, and 11.0% of the cells incubated with AβpE3-40 were in the 
upper right quadrant. Unlike N9 cells in which uptake of AβpE3-40 was the 
highest, the uptake of AβpE3-40 was the lowest in primary microglia. 
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Figure 4. Uptake of Aβ
x-40
 in N9 Cells Using FACS 
N9 cells were incubated with 488 fluorescently labeled Aβ
1-40
, Aβ
3-40
, and 
Aβ
pE3-40
 and a fluorescently labeled anti-CD11b antibody for one hour and 
then analyzed using FACS. CD11b is a cell-surface microglial cell marker. 
The IgG2b isotope serves as a baseline by which the fluorescence is 
measured. Cells positive for CD11b are shifted to the right and cells 
positive for fluorescently-labeled Aβ
x-40
 are shifted up. Cells positive for 
both CD11b and fluorescently-labeled Aβ
1-40
 appear in the upper right 
quadrant. All of the FACS experiments using the N9 cells were performed 
on the same day. 
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Figure 5. Uptake of Aβ
x-40
 in Primary Microglia Using FACS 
Primary microglia were incubated with 488 fluorescently labeled Aβ
1-40
, Aβ
3-40
, and Aβ
pE3-40
 and a fluorescently labeled anti-CD11b 
antibody for one hour and then analyzed using FACS. CD11b is a cell-surface microglial cell marker. The IgG2b isotope serves as a 
baseline by which the fluorescence is measured. Cells positive for CD11b are shifted to the right and cells positive for fluorescently-
labeled Aβ
x-40
 are shifted up. Cells positive for both CD11b and fluorescently-labeled Aβ
1-40
 appear in the upper right quadrant. The 
FACS experiments using the primary microglia were performed on three separate days. 
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Aβx-40 in Microglia Appears to be Intracellular by Immunofluorescence 
 In order to confirm the results shown by FACS and determine if Aβx-40 is 
in fact internalized by microglia, fluorescently-labeled Aβx-40 peptides were 
applied to N9 and primary microglia for one hour. Confocal microscopy was 
used to determine if Aβx-40 peptides were co-localized with the cell interior. Cells 
were counterstained for CD11b to clearly show the cell surface.  
Figures 6-8 show the uptake of FLfAβx-40 by N9 cells after one hour. As 
shown in Figure 6, the uptake of FLfAβ1-40 increases as the concentration is 
increased from 0.5 µM to 8 µM. A Z-stack was obtained for each peptide at the 8 
µM concentration to confirm that the peptide is internalized after a period of one 
hour. This is clearly shown in panel D of Figure 6. A similar trend is observed in 
Figure 7 for FLfAβ3-40, where the amount of intracellular Aβ increases as the 
concentration is increased, and in Figure 8 for FLfAβpE3-40, though to a lesser 
extent than the other two peptides. Figures 9-11 show the uptake of FLfAβx-40 by 
primary microglia after one hour. All three peptides show increased intracellular 
Aβ at the 8 μM concentration, but in an opposite trend than seen with the N9 
cells. FLfAβpE3-40 (Figure 11) appeared to have the most intracellular Aβ at the 8 
μM concentration compared to the other two peptides (Figures 9 and 10).  
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Figure 6. Uptake of FLfAβ
1-40
 by N9 Shown by IF 
The uptake of 488-labeled Aβ
1-40
 (shown in green) increases as the 
concentration is increased from 0.5 μM (B) to 8 μM (C). The orthogonal Z-
stack at the 8 μM concentration reveals that the Aβ is intracellular.  The 
cells were counterstained with an anti-CD11b (red, Alexa Fluor 594) 
antibody to clearly show the cell surface. The cells shown in panel A were 
not treated with Aβ and serve as a negative control. 
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Figure 7. Uptake of FLfAβ
3-40
 by N9 Shown by IF 
The uptake of 488-labeled Aβ
3-40
 (shown in green) increases as the 
concentration is increased from 0.5 μM (B) to 8 μM (C). The orthogonal Z-
stack at the 8 μM concentration reveals that the Aβ is intracellular (D).  The 
cells were counterstained with an anti-CD11b (red, Alexa Fluor 594) antibody 
to clearly show the cell surface. The cells shown in panel A were not treated 
with Aβ and serve as a negative control. 
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Figure 8. Uptake of FLfAβ
pE3-40
 by N9 Shown by IF 
The uptake of 488-labeled Aβ
pE3-40
 (shown in green) increases as the 
concentration is increased from 0.5 μM (B) to 8 μM (C). The orthogonal Z-
stack at the 8 μM concentration reveals that the Aβ is intracellular (D).  The 
cells were counterstained with an anti-CD11b (red, Alexa Fluor 594) 
antibody to clearly show the cell surface. The cells shown in panel A were 
not treated with Aβ and serve as a negative control. 
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Figure 9. Uptake of FLfAβ
1-40
 by Primary Microglia Shown by IF 
The uptake of 488-labeled Aβ
1-40
 (shown in green) does not seem to increase as 
the concentration is increased from 0.5 μM (B) to 8 μM (C), as it does with Aβ
3-40
 
or Aβ
pE3-40
. The cells were counterstained with an anti-CD11b (red, Alexa Fluor 
594) antibody to clearly show the cell surface. The cells shown in panel A were 
not treated with Aβ and serve as a negative control. 
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Figure 10. Uptake of FLfAβ
3-40
 by Primary Microglia Shown by IF 
The uptake of 488-labeled Aβ
3-40
 (shown in green) increases as the concentration 
is increased from 0.5 μM (B) to 8 μM (C). The orthogonal Z-stack at the 8 μM 
concentration reveals that the Aβ is intracellular (D).  The cells were 
counterstained with an anti-CD11b (red, Alexa Fluor 594) antibody to clearly 
show the cell surface. The cells shown in panel A were not treated with Aβ and 
serve as a negative control. 
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Figure 11. Uptake of FLfAβ
pE3-40
 by Primary Microglia Shown by IF 
The uptake of 488-labeled Aβ
pE3-40
 (shown in green) increases as the 
concentration is increased from 0.5 μM (B) to 8 μM (C). The Z-stack of the 8 μM 
concentration reveals that the Aβ is intracellular (D).  The cells were 
counterstained with an anti-CD11b (red, Alexa Fluor 594) antibody to delineate 
the cell surface. The cells shown in panel A were not treated with Aβ and serve 
as a negative control. 
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The Uptake and Degradation of Aβx-40 by Microglia Differs Between Variants  
 An Aβ uptake and degradation assay was performed as described in the 
Materials and Methods section. Aβx-40 uptake was determined by collecting a 
sample of the medium and cell lysate one hour after applying the peptide. 
Samples of medium and cell lysate were also collected one, three, and six hours 
after new medium was added to the cells to determine the amount of 
degradation of Aβx-40. An uptake/degradation experiment was performed using 
both N9 (total of 3 experiments) and primary microglia (1 experiment) for 
monomeric and fibrillar Aβ1-40, Aβ3-40, and AβpE3-40.  
 Figure 12 shows the data for the monomeric Aβx-40 uptake/degradation 
experiments and Figure 14 shows the data for the fibrillar Aβx-40 
uptake/degradation experiments, both using N9 cells. Each experiment was 
conducted three times and the data were analyzed by one-way repeated 
measures ANOVA and Tukey post-hoc test (p<0.001, ** p<0.01, * p<0.05). Figure 
12 shows a significant decrease in the intracellular Aβ1-40 in all three washout 
steps (panel B) and a significant decrease in the intracellular AβpE3-40 in all three 
washout steps (panel F). The monomeric Aβ3-40 experiment shown in Figure 12 
does not show any significant decrease, but this is likely due to a technical error 
while running the experiment. Figure 14 shows a significant decrease in fibrillar 
Aβ3-40 between the one hour incubation and the six hour washout time points 
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(panel D).  The other two peptides, Aβ1-40 (panel B) and AβpE3-40 (panel F) show an 
increase in the amount of intracellular peptide in the washout steps when 
compared to the one hour incubation time point.  
 Figure 13 shows the data for the monomeric Aβx-40 uptake/degradation 
experiments and Figure 15 shows the data for the fibrillar Aβx-40 
uptake/degradation experiments, both using primary microglia. Since each 
experiment was only conducted once, no statistics were performed, but there are 
trends that can be discussed. Figure 13 shows the uptake experiments using 
monomeric Aβ1-40, Aβ3-40, and AβpE3-40. All three peptides show a decreased 
amount of intracellular Aβ when compared to the 1 hour incubation time point. 
This indicates that all three peptides are degraded by microglia after they are 
internalized, though AβpE3-40 seems to be degraded less efficiently than the other 
peptides. According to Figure 15, which shows the data for the fibrillar Aβx-40 
peptides, there is less intracellular Aβ1-40 as the experiment proceeds to 
completion (panels A and B). The remaining two peptides, however, seem to 
accumulate intracellularly as the experiment proceeds to completion. 
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Figure 12. Uptake and Degradation of Monomeric Aβ
x-40
 by N9 Microglia 
Uptake of monomeric Aβ
1-40
 (A), Aβ
3-40
 (C), and Aβ
pE3-40
 (E) by primary microglia is shown by western blot. Bands corresponding to Aβ were normalized to a 
GAPDH loading control. To determine the degradation of each peptide, the integrated intensity is an average of three experiments and is expressed as a 
SEM, and the graphs are shown for Aβ
1-40
 (B), Aβ
3-40
 (D), and Aβ
pE3-40
 (F) below the corresponding western blot. Integrated intensity values for the 1 hour 
washout, 3 hour washout, and 6 hour washout steps were further normalized to the 1 hour incubation time point. Data were analyzed by one-way repeated 
measures ANOVA and Tukey post-hoc tests, *** p<0.001, ** p<0.01, * p<0.05. 
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Figure 13. Uptake and Degradation of Monomeric Aβ
x-40
 by Primary Microglia 
Uptake of monomeric Aβ
1-40
 (A), Aβ
3-40
 (C), and Aβ
pE3-40
 (E) by primary microglia is shown by western blot. Bands corresponding to Aβ were 
normalized to a GAPDH loading control. The integrated intensity is expressed as a SEM, and the graphs are shown for Aβ
1-40
 (B), Aβ
3-40
 (D), 
and Aβ
pE3-40
 (F) below the corresponding western blot.  To determine the amount of peptide degradation, integrated intensity values for the 
1 hour washout, 3 hour washout, and 6 hour washout steps were further normalized to the 1 hour incubation time point. 
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Figure 14. Uptake and Degradation of Fibrillar Aβ
x-40
 by N9 Microglia 
Uptake of fibrillar Aβ
1-40
 (A), Aβ
3-40
 (C), and Aβ
pE3-40
 (E) by primary microglia is shown by western blot. Bands corresponding to Aβ were 
normalized to a GAPDH loading control. To determine the degradation of each peptide, the integrated intensity is an average of three 
experiments and is expressed as a SEM, and the graphs are shown for Aβ
1-40
 (B), Aβ
3-40
 (D), and Aβ
pE3-40
 (F) below the corresponding western blot. 
Integrated intensity values for the 1 hour washout, 3 hour washout, and 6 hour washout steps were further normalized to the 1 hour incubation 
time point. Data were analyzed by one-way repeated measures ANOVA and Tukey post-hoc tests, *** p<0.001, ** p<0.01, * p<0.05. 
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Figure 15. Uptake and degradation of Fibrillar Aβ
x-40
 by Primary Microglia 
Uptake of fibrillar Aβ
1-40
 (A), Aβ
3-40
 (C), and Aβ
pE3-40
 (E) by primary microglia is shown by western blot. Bands corresponding to Aβ were 
normalized to a GAPDH loading control. To determine the degradation of each peptide, the integrated intensity is expressed as a SEM, and the 
graphs are shown for Aβ
1-40
 (B), Aβ
3-40
 (D), and Aβ
pE3-40
 (F) below the corresponding western blot. Integrated intensity values for the 1 hour 
washout, 3 hour washout, and 6 hour washout steps were further normalized to the 1 hour incubation time point. 
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DISCUSSION 
Although it is difficult to make definitive statements based on the data 
presented, there are nevertheless several conclusions that can be proposed. The 
first is that N9 cells and primary microglia take up and degrade the three Aβ 
peptides differently. This is apparent when looking at the FACS, IF, and Western 
blot experiments. According to Western blot and IF, primary microglia seem to 
prefer to take up AβpE3-40, whereas N9 cells seem to prefer to take up Aβ1-40. These 
results are not consistent with the FACS data that indicate that N9 cells 
preferentially take up AβpE3-40 compared to Aβ1-40 and Aβ3-40. In contrast, primary 
microglia seem to preferentially take up AβpE3-40 compared to Aβ3-40 and Aβ1-40 
according to the IF and Western blot results. This is, again, not consistent with 
the FACS data, as primary microglia appear to preferentially take up Aβ1-40 
compared to Aβ3-40 and AβpE3-40. 
 One reason for the decreased uptake of Aβ1-40 by N9 cells as shown by 
FACS could be due to a technical error that occurred while generating the 
fibrillar Aβ1-40. For some reason, during the generation of the fibrils, some of the 
Aβ1-40 was lost, causing the concentration of fibrillar Aβ1-40 to be lower than 
expected. This in turn would cause a lower than expected number of cells 
positive for FLfAβ1-40 during the FACS analysis. This should not affect the final 
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result, however, as FACS results are reported as the percent of cells taking up the 
Aβ peptide. 
Alternatively, it could be possible that Aβx-40 stuck to the cell surface, and 
in particular, sticky AβpE3-40 could interfere with the results. This could be 
especially true when it comes to interpreting the FACS data. Accutase was the 
enzyme used to detach the cells from the cell culture surface for FACS analysis. 
Accutase is known to detach cells from plastic while preventing any cell-surface 
markers, such as CD11b, from being cleaved off. Trypsin is also used to detach 
cells from plastic for FACS, but it is known to be much harsher than Accutase, 
and can cleave off proteins bound to the cell surface if not used carefully. 
Keeping that in mind, it is possible that there could be some Aβ stuck to the cell 
surface that was not cleaved off when Accutase was used to detach the cells from 
the cell surface. Since FACS cannot distinguish between peptide attached to the 
cell surface and peptides internalized by the cell, it is possible that our data 
reflect not only cells that have internalized Aβ, but also cells that have Aβ 
attached to the cell surface. 
The second possible conclusion that can be drawn from the presented data 
is that overall, N9 cells appear to prefer to take up Aβ1-40, whereas primary 
microglia prefer to take up AβpE3-40 as previously discussed. This is consistent 
with both the IF and Western blot data. Although this conclusion is not 
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consistent with the FACS data presented, it is possible that these results are not 
entirely correct due to one of the factors mentioned above, whether a lower 
concentration of FLfAβ1-40 than expected or sticking of the peptide to the cell 
surface. The Western blot data does seem to show, however, that monomeric 
Aβ1-40 and AβpE3-40 are more efficiently degraded by N9 cells than their fibrillar 
forms. It is difficult to draw a conclusion about the differences in uptake and 
degradation between the monomeric and fibrillar forms of Aβ3-40 due to a 
technical error during one of the experiments that caused no Aβ3-40 to be present 
in the cell lysate after the one hour incubation step. 
Statistical analysis on the N9 western blots show a significant decrease of 
in the amount of monomeric Aβ1-40 and AβpE3-40 in the cell lysate between the 1 
hour incubation and the 1 hour, 3 hour, and 6 hour washouts time points. These 
data suggest that N9 cells efficiently take up and degrade monomeric Aβ1-40 and 
AβpE3-40. In addition, there is a significant decrease in the amount of fibrillar Aβ3-
40 in the cell lysate between the 1 hour incubation and the 6 hour washout time 
points. There is not a statistically significant decrease in the amount of fibrillar 
Aβ1-40 or AβpE3-40, but this could be due to a technical error during the 
experiments. In order to confirm the observed results, additional Western blot 
experiments should be conducted using the same parameters. 
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Another interesting observation seen in the Western blot data is the 
apparent intracellular accumulation of fibrillar Aβ3-40 and AβpE3-40 during the 
washout steps in the experiment using primary microglia (Figure 15), albeit this 
experiment was performed only once in this study. This apparent increase could 
be due to a number of factors. First, there could be a faster aggregation of these 
fibrils within the cell which helps them avoid being broken down. Second, there 
could have been a problem with the well representing the 1 hour incubation 
period during the experiment, causing less uptake of peptide than expected. 
Finally, there could have been a technical error during the Western blot portion 
of the experiment, causing the values for the amount of peptide in the cell lysate 
of the washout steps to be greater than expected. 
Future in vitro experiments could be conducted using anti-Aβ antibodies 
to see if a difference in uptake or degradation of Aβ by microglia could be 
detected. Passive immunotherapy has been shown to decrease plaque load in 
vivo, so an in vitro study could help us more clearly discern the differences in 
antibody-mediated uptake between the three Aβx-40 peptides and using different 
antibodies. This study could also be repeated using different C-terminal variants, 
namely the Aβx-42 peptide, which is the most abundant form in plaques. An in 
vitro experiment comparing the uptake and degradation of Aβx-40 and Aβx-42 
could show how and if microglia process these C-terminal variants differently. 
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This could be useful in determining how microglia process the different Aβ 
variants that they come across in plaques in vivo.   
Future experiments could also help further distinguish the differences 
between uptake and degradation of Aβ peptides. To do this, we would need to 
know the mechanism by which Aβ is taken up by the microglia cell, e.g., by 
which receptor signaling pathway. Since this process is not yet well documented 
in the literature, a large study would need to be conducted to determine this 
mechanism.  
Although it is difficult to make definitive statements from the data 
presented, the trends discussed could be useful in developing further studies 
aimed at testing microglial uptake and degradation of Aβ. If these peptides can 
be targeted for degradation while preventing damage to the surrounding tissue, 
the perhaps some of the cognitive side effects of neuronal damage can be 
prevented. Although there is still no effective cure for Alzheimer’s disease, every 
new piece of information that we gain brings us one step closer. 
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